A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and ...

Growth stocks, particularly those in the biotech sector, can be lucrative long-term investments. The biotech sector often ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may ...

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I ...

BeyondSpring Inc.’s BYSI share price has dipped by 7.30%, which has investors questioning if this is right time to buy.